Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8263MR)

This product GTTS-WQ8263MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8263MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9196MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ3336MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-001
GTTS-WQ10129MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ14484MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RYI-018
GTTS-WQ4663MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986036
GTTS-WQ6066MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ290MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ7234MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW